Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach

An article to present how cancer patients were taken in charge at Lyon University Hospital Cancer Institute (France) during the first peak of the COVID-19 pandemic between March and May 2020 is under writing.

It will present strategies that were set-up to avoid cross-contamination between patients and caregivers, patients treatment adaptation (timing, dosage,..) and how consultations, multidisciplinary team meetings, surgical procedures and clinical trials were impacted.

Part of this article will also illustrate the characteristics of patients with a solid tumor(s) that have been hospitalized during this timeframe for the COVID-19. How cancer type and stage affect Covid severity and mortality.will be described for a small sample of patients (44). These qualitative figures will be compared to literature current state of the art.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer COVID-19 Coronaviridae Infections Coronavirus Infections Covid19 Infections Lung Diseases Neoplasms Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Solid Tumor Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lyon University Hospital Cancer Institute

Bron, 69 677, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with a LUHCI code created after 2015 and a LUHCI COVID-19 code created between March 2020 and May 2020.

Exclusion criteria

Patients who did not allow the reuse of their medical file data for research related to COVID-19-

Treatment and study plan

COCA is an observational study based on retrospective data issued from patient medial file.

Other

The following parameters will be collected from the medical files of the patients involved in this study:

Age
Gender
Cancer type
Cancer Stage
Cancer Treatment
COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)
Living Status
Attribution of Mortality to COVID status
Comorbidities

Primary outcomes

Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age.

Time frame: At the end of Month 1

COVID-19 severity will be determined based on chest X-Ray damage as follow. Low severity : ≤25% of chest X-Ray damage, Middle severity: between 25-50% of chest X-Ray damage, High Severity : above 50% of chest X-Ray damage.

A graphic will then be drafted to present the relationship between Covid-19 severity depending on patient age, cancer nature, and cancer stage.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: COCA

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2021
First posted: Jun 2, 2021
Registry last updated: Jun 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed